Braidwell LP Nuvalent, Inc. Transaction History
Braidwell LP
- $1.63 Billion
- Q2 2025
A detailed history of Braidwell LP transactions in Nuvalent, Inc. stock. As of the latest transaction made, Braidwell LP holds 1,175,876 shares of NUVL stock, worth $115 Million. This represents 5.49% of its overall portfolio holdings.
Number of Shares
1,175,876
Previous 840,945
39.83%
Holding current value
$115 Million
Previous $59.6 Million
50.44%
% of portfolio
5.49%
Previous 3.66%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
227Shares Held
59.8MCall Options Held
191KPut Options Held
306K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.76 Billion31.57% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$516 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$443 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$296 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$176 Million0.02% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.21B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...